A randomized multicentered phase II study to evaluate SHR-1210 (PD-1 antibody) in subjects with advanced hepatocellular carcinoma (HCC) who failed or intolerable to prior systemic treatment

Saved in:
Bibliographic Details
Published inAnnals of oncology Vol. 29; pp. viii719 - viii720
Main Authors Qin, S.K., Ren, Z.G., Meng, Z.Q., Chen, Z.D., Chai, X.L., Xiong, J.P., Bai, Y.X., Yang, L., Zhu, H., Fang, W.J., Lin, X.Y., Chen, X.M., Li, E.X., Xia, Y., Zou, J.J.
Format Journal Article
LanguageEnglish
Published England Elsevier Ltd 01.10.2018
Online AccessGet full text

Cover

More Information
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0923-7534
1569-8041
DOI:10.1093/annonc/mdy424.029